The microbiome revolution

Bookmark and Share
Published: 21 Sep 2017
Views: 1693
Mr James Kinross - Imperial College London, London, UK

Mr James Kinross talks to ecancer at the Microbiome in Cancer and Beyond 2017 meeting about the microbiome's role in the treatment of cancer, determining the toxicity of certain treatments, and influencing the development of resistance to chemotherapeutics.

Mr Kinross speaks of the microbiome revolution, where we have come to realise how important the microbiome is in influencing cancer. He underlines the enormous diversity of the microbiome, as well as it's specificity to each individual. This means it must be taken into account when designing drugs, as we simply cannot rely on solely genetic understanding. 

In the initial phase of microbiome research in cancer the focus was really on its role in aetiology but there has been a shift towards trying to understand what the microbiome’s role is in defining how effective treatment is, how good it is at curing cancer, but also what role it has in trying to determine how toxic a treatment might be or whether or not, indeed, it might influence the ability of individuals to develop resistance to certain chemotherapeutics. In many ways this field has been rediscovered. If you go back 30-40 years there were some excellent metabolism studies where scientists were very aware of the role of the microbiome, in fact took advantage of it. So they understood that the microbiome had specific metabolic functions and you could create prodrugs which then get metabolised into active drugs. But what the microbiome revolution, I think you can call it, in the last few years has told us is that actually their importance is much more subtle and it’s very, very diverse and it’s highly individualised. It’s much more than just drug metabolism. It influences the immune response, for example, to many types of cancer therapies.

When else is understanding the microbiome particularly important?

There is a significant drive towards personalised healthcare and this is a common theme and you hear that a lot in cancer therapy, how you get the right drug for the right patient at the right time. But my belief is that you can’t have personalised therapy without understanding what the microbiome does because it is so individualised, it is so specific and it is so bioactive. So if you’re just doing pharmacogenomics and you’re just interested in what an individual’s genes are doing and you’re trying to design drugs based on someone’s genes, you’re missing really an awful lot of what’s defining how effective that drug is. So you’ve got to study the microbiome and that’s why it’s so important.